Vericel Stock News

New York State Teachers Retirement System increased its stake in shares of Vericel Co. (NASDAQ:VCEL) by 0.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 45,424 shares of the biotechnology companys stock after acquiring an additional 424 shares during the quarter. New York State Teachers Retirement Systems holdings in Vericel were worth $2,217,000 [] The post New York State Teachers Retirement System Buys 424 Shares of Vericel Co. (NASDAQ:VCEL) appeared first on ETF Daily News .

Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Profitability This table compares Titan Pharmaceuticals and Vericels net margins, return on equity and return on [] The post Comparing Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) appeared first on ETF Daily News .

Analysts expect that Vericel Co. (NASDAQ:VCEL) will announce earnings of $0.20 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Vericels earnings, with the lowest EPS estimate coming in at $0.17 and the highest estimate coming in at $0.22. Vericel reported earnings of $0.25 per share during []

Vericel (NASDAQ:VCEL) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk. Profitability This table compares Vericel and Titan Pharmaceuticals net margins, return on equity and return on []

This global Cartilage Repair/ Cartilage Regeneration market report is the precise depiction of obstructions, drivers or trends that affect the market either positively or negatively. It offers for the scope of other applications that may influence the market situation further.

Perkins Capital Management Inc. reduced its position in shares of Vericel Co. (NASDAQ:VCEL) by 4.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 75,387 shares of the biotechnology companys stock after selling 3,225 shares during the quarter. Vericel accounts for about 2.3% of Perkins Capital Management Inc.s investment portfolio, making the stock []

Vericel Co. (NASDAQ:VCEL) Director Steven C. Gilman sold 5,000 shares of the stock in a transaction on Monday, November 29th. The shares were sold at an average price of $39.17, for a total value of $195,850.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Vericel []

Equities analysts predict that Vericel Co. (NASDAQ:VCEL) will post earnings per share of $0.20 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vericels earnings, with the lowest EPS estimate coming in at $0.17 and the highest estimate coming in at $0.22. Vericel reported earnings per share of []

This is a reversal of the price action on the previous day, in which price moved down. The post Vericel Corp (VCEL): Price Now Near $39.11; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .

Knee Cartilage Damage Repair Market research report is wide-ranging and object-oriented which is framed after the combination of an admirable industry experience, talent solutions, industry insight, and most modern tools and technology. A thorough analysis has been performed in this

Invesco Ltd. trimmed its position in shares of Vericel Co. (NASDAQ:VCEL) by 37.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 432,649 shares of the biotechnology companys stock after selling 256,976 shares during the period. Invesco Ltd. owned 0.93% of Vericel worth $22,714,000 []

Zacks Investment Research upgraded shares of Vericel (NASDAQ:VCEL) from a sell rating to a hold rating in a research report released on Saturday morning, Zacks.com reports. According to Zacks, Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two []

Vericel Co. (NASDAQ:VCEL) was the target of unusually large options trading on Friday. Investors purchased 4,195 put options on the stock. This is an increase of 2,297% compared to the typical daily volume of 175 put options. In other news, Director Steven C. Gilman sold 5,000 shares of the firms stock in a transaction dated []

Royal Bank of Canada grew its position in Vericel Co. (NASDAQ:VCEL) by 169.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 96,615 shares of the biotechnology companys stock after acquiring an additional 60,722 shares during the period. Royal Bank of Canadas holdings in Vericel []